NCT07237685 Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus
| NCT ID | NCT07237685 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Condition | Type 2 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-06-06 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-06-06 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
People with type 2 diabetes have a much higher risk of heart disease. One common problem is when the blood vessels that supply the heart become narrowed or blocked by fatty deposits, called plaque. This makes it harder for blood to reach the heart and can lead to serious problems such as chest pain, heart attacks, or even death. This study will follow people with type 2 diabetes who have already had a special heart scan called a coronary CT angiography. This scan takes detailed pictures of the heart's blood vessels. The goal is to understand how heart disease changes over time in people with type 2 diabetes, by looking at repeat scans and other health information. By learning more about how plaque builds up or gets worse, researchers hope to find better ways to identify which patients are most at risk for future heart problems.
Eligibility Criteria
Inclusion Criteria: * Age over 18 years * Previous completion of CCTA scan for CAD assessment * Diagnosed with Type 2 Diabetes and currently receiving glucose lowering treatment * Sufficient image quality of the CCTA scan (at least 2/3 vessels of sufficient quality for assessment). Exclusion Criteria: * Inability to provide written informed consent * Presence of an unstable condition * Ingeligibility for CCTA acquisition due to severe renal dysfunction (eGFR ≤ 30 mL/min/1.73m²) or known hypersensitivity or contraindication to CT contrast agents * Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study * Baseline (routine care) CCTA performed \< 2 years or \> 5 years before inclusion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07237685 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07237685 currently recruiting?
Yes, NCT07237685 is actively recruiting participants. Contact the research team at w.r.vandevijver@amsterdamumc.nl for enrollment information.
Where is the NCT07237685 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands, Amsterdam, Netherlands.
Who is sponsoring the NCT07237685 clinical trial?
NCT07237685 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.